Compare TEVA & BDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TEVA | BDX |
|---|---|---|
| Founded | 1901 | 1897 |
| Country | Israel | United States |
| Employees | 32842 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.9B | 40.3B |
| IPO Year | N/A | 1997 |
| Metric | TEVA | BDX |
|---|---|---|
| Price | $32.98 | $144.97 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 13 |
| Target Price | $38.63 | ★ $186.00 |
| AVG Volume (30 Days) | ★ 4.7M | 2.3M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 2.89% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.25 |
| Revenue | N/A | ★ $21,840,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.97 | $3.02 |
| P/E Ratio | ★ $28.19 | $582.08 |
| Revenue Growth | N/A | ★ 8.24 |
| 52 Week Low | $14.99 | $141.82 |
| 52 Week High | $37.35 | $213.08 |
| Indicator | TEVA | BDX |
|---|---|---|
| Relative Strength Index (RSI) | 43.90 | 43.24 |
| Support Level | $30.53 | $142.48 |
| Resistance Level | $35.37 | $153.09 |
| Average True Range (ATR) | 1.15 | 3.07 |
| MACD | -0.14 | -0.03 |
| Stochastic Oscillator | 18.99 | 18.50 |
Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
Becton Dickinson operates in four business units. Medical essentials (35% of total sales) includes the legacy medical surgical unit, which sells catheters, syringes, and infection prevention products. Connected care (24%) core products include the Alaris infusion pump, Pyxis dispensing system, and pharmacy automation platforms. Biopharma systems (13%) produces prefillable syringes and autoinjectors. Interventional (29%) is composed of the surgery, peripheral vascular, and urology segments. More than 60% of revenue comes from the United States.